Related Experiment Video

Updated: Jun 10, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil

Matthias Schaier1, Christian Scholl, Dominik Scharpf

  • 1Department of Nephrology, University of Heidelberg, Heidelberg, Germany. matthias_schaier@med.uni-heidelberg.de

Rheumatology (Oxford, England)
|July 31, 2010
PubMed
Abstract

Insights

Proton pump inhibitors (PPIs) significantly reduce mycophenolate mofetil (MMF) absorption and immunosuppressive effects in autoimmune disease patients. This drug interaction necessitates careful consideration for MMF therapy efficacy.

Area of Science:

  • Pharmacology
  • Immunology
  • Gastroenterology

Background:

  • Mycophenolate mofetil (MMF) is a crucial immunosuppressant for autoimmune diseases.
  • MMF is absorbed in the stomach, but proton pump inhibitors (PPIs) increase gastric pH, potentially affecting absorption.
  • The widespread use of PPIs warrants an investigation into their impact on MMF bioavailability.

Purpose of the Study:

  • To determine if co-administration of pantoprazole (a PPI) affects MMF absorption and immunosuppressive potency.
  • To assess the clinical implications of PPI use in patients on MMF maintenance therapy.

Main Methods:

  • Analyzed 36 autoimmune disease patients on stable MMF therapy.
  • Compared 23 patients on pantoprazole with 13 patients not on PPIs.
  • Measured mycophenolic acid levels and IMPDH activity via HPLC in plasma samples over 12 hours.

Main Results:

  • MMF total area under the curve was 37% lower in PPI patients (P < 0.01).
  • Maximum MMF peak concentration was 60% lower in pantoprazole patients (P < 0.001).
  • IMPDH enzyme activity was 42% higher in PPI patients (P < 0.01), indicating reduced immunosuppression.

Conclusions:

  • Pantoprazole significantly reduces MMF exposure and immunosuppressive potency in autoimmune patients.
  • This interaction may explain variable treatment outcomes in studies using MMF.
  • Clinicians should consider PPI use when prescribing MMF for autoimmune conditions.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.